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Abstract
Mesenchymal stromal cells are emerging as an extremely promising therapeutic agent for tissue regeneration due to their
multi-potency, immune-modulation and secretome activities, but safety remains one of the main concerns, particularly
when in vitro manipulation, such as cell expansion, is performed before clinical application. Indeed, it is well documented
that in vitro expansion reduces replicative potential and some multi-potency and promotes cell senescence. Furthermore,
during in vitro aging there is a decrease in DNA synthesis and repair efficiency thus leading to DNA damage accumulation
and possibly inducing genomic instability. The European Research Project ADIPOA aims at validating an innovative cell-
based therapy where autologous adipose stromal cells (ASCs) are injected in the diseased articulation to activate
regeneration of the cartilage. The primary objective of this paper was to assess the safety of cultured ASCs. The
maintenance of genetic integrity was evaluated during in vitro culture by karyotype and microsatellite instability analysis. In
addition, RT-PCR array-based evaluation of the expression of genes related to DNA damage signaling pathways was
performed. Finally, the senescence and replicative potential of cultured cells was evaluated by telomere length and
telomerase activity assessment, whereas anchorage-independent clone development was tested in vitro by soft agar
growth. We found that cultured ASCs do not show genetic alterations and replicative senescence during the period of
observation, nor anchorage-independent growth, supporting an argument for the safety of ASCs for clinical use.
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Introduction
Mesenchymal Stromal Cells (MSCs) are a population of
adherent cells that are able to differentiate into mesenchymal
lineages (cartilage, bone and fat tissue), as well as into other types
of lineages not derived from the mesodermal layer [1].
MSCs obtained from bone marrow (BM) represent a standard
in the field of adult stem cell biology and clinical applications;
however, stromal cells obtained from adipose tissue are becoming
an attractive alternative due to their minimally invasive accessi-
bility and plentiful availability.
Adipose tissue originates from mesodermal germ layer and it is
the most shared connective tissue in humans. It is mainly
distributed as subcutaneous and visceral fat [2] and its removal
(generally by liposuction) supplies a large amount of mesenchymal
stem cells, for regenerative medicine purposes (about 300,000/ml)
[3,4].
The enzymatic digestion of adipose tissue releases a heteroge-
neous mix of cells, the stromal vascular fraction (SVF), which
contains the stromal population of adipose derived stromal cells
[5]. The culture of the crude SVF allows the expansion of a
relatively homogeneous fibroblastic-like population, adherent to
plastic, with a wide proliferative capacity and a stromal surface
phenotype [6,7], potentially differentiating in multiple lineages [8–
12]. This population is identified as adipose-derived stromal/stem
cells (ASCs), according to IFATS’s recommendations [13,14].
ASCs share a lot of similarities, such as morphology, distribution
of surface antigens and multi-potency with other stem cells
obtained, for example, from BM or umbilical cord blood [15].
The European Regulation defines the use of mesenchymal stem
cells (either derived from BM or from adipose tissue) as advanced
therapy medicinal products (DIRECTIVE 2001/83/EC of the
European Parliament and of the Council of 6 November 2001 on
the Community Code Relating to Medicinal Products for Human
Use. Available from URL: http://www.emea.europa.eu/pdfs/
human/pmf/2001-83-EC.pdf; Regulation (EC) no 1394/2007 of
the European Parliament and of the Council. Available from
URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ).
The production of clinical-grade MSCs in agreement with
GMP procedures requires the careful identification and control of
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all the phases of cell manipulation and release. In addition to
bacteriological tests, that attest the sterility of the cell product, the
methods of expansion must assure and maintain the phenotypic
and functional characteristics of the cells as well as their genomic
stability during the in vitro culture period [16–19].
The spontaneous transformation of human mesenchymal stem
cells during in vitro expansion remains a major safety problem
[1,17–18,20]. Several studies pointed to the safety of cultured
human mesenchymal stem cells by molecular evaluation of
genomic stability [21–22] and by evaluating tumorigenicity in vivo
[23–28]. It is demonstrated that in vitro-expanded human MSC
acquire chromosomal aberrations [23,29–33] and there is still an
open debate about the relevance of these alterations. Some authors
argue the irrelevance of these modifications and their transient
nature [30,33–34], whereas others suggest particular caution when
interpreting these findings [31,35]. However, at present very few
data were provided about human MSC transformation in culture
[36] and two impressive studies describing malignant transforma-
tion were subsequently retracted by the authors [37–40].
The aim of this study was to evaluate the potential susceptibility
of in vitro expanded ASC to genetic alterations at different in vitro
culture time points due to the effect of in vitro ageing, replicative
stress and culture conditions to define appropriate quality controls
and release criteria for the clinical use of these cells. ASC isolation
and culture were performed according to GMP and in agreement
with the UE ADIPOA project, which involves the present authors
and concerning an innovative cell-based therapy for cartilage
regeneration in knee osteoarthritis by ASC injection in the
diseased articulation.
To impose extreme conditions on cells, longer observation times
were chosen intentionally compared with those defined for
releasing cells for clinical applications (i.e. the end of P1,
corresponding to 14 days of culture).
To evaluate genetic integrity of in vitro-expanded ASCs, DNA
damage accumulation was analyzed both at chromosome and
molecular levels, by karyotype and MicroSatellite Instability (MSI)
analysis, respectively. Karyotyping is the gold standard to evaluate
gross DNA alterations, but possible small molecular changes are
not detected by this technique. The MisMatch Repair (MMR)
System is the main post-replicative correction pathway whose
efficiency can be monitored by MSI analysis. The rationale to
evaluate this repair system lies in its fundamental role for genomic
stability maintenance [41–43] in actively replicating cells such as
those being studied. In addition, both oxidative stress (known to be
induced by culture conditions) [44–46] and in vitro/in vivo aging
[47–50] were shown to be capable of altering MMR system
efficiency, thus leading to genetic instability. Therefore, MSI
analysis might be used as a possible biosafety marker of long-term
culture genetic stability at molecular level. Besides these investi-
gations, RT-PCR array-based evaluation of the expression of
genes related to DNA damage and repair was performed.
Finally, the senescence and replicative potential of cultured cells
was evaluated by telomere length and telomerase activity
assessment, whereas anchorage-independent clone development
was tested in vitro by soft agar growth.
The present results argue in favor of the safety of ASC-cultured
cells for clinical applications.
Materials and Methods
Ethics Statement
Research was performed in the context of the AdipoA EU FP7
project, under the approval of AFSSAPS (Agence franc¸aise de
se´curite´ sanitaire des produits de sante´), reference n. TC301 of
December 28, 2011, with donor written informed consent. Patient
names were replaced by arbitrary codes to remain anonymous.
ASC Isolation and Culture
Clinical grade ASCs were isolated from 6 donor lipoaspirates
(A–F) according to Good Manufacturing Practice (GMP) as
described [51]. Informed consent was obtained from all donors.
Briefly, the adipose tissue (3061 g) was harvested by liposuction
under local anesthesia. All donors (1 woman and 5 men, mean age
6 SD: 66620 years, mean Body Mass Index 6 SD: 2662.1 Kg/
m2) gave their informed consent to the study. Fat was digested with
collagenase NB6 GMP-grade from C. histolyticum (Serva Elecro-
phoresis, Germany) at 37uC for 45 minutes and centrifuged
(6006g for 10 min). The SVF was seeded into a CellStackTM
(Corning, France) chamber at the density of 46103 cell/cm2 in a-
MEM supplemented with platelet lysate (PLP) (EFS-PM own
production). On day 8, the cells were trypsinized and expanded at
26103 cells/cm2 until day 14 (end of passage 1). Cell counting and
viability were performed using trypan blue exclusion dye on day 8
and 14. The mean number of cells recovered after 14 days was
2.3610860.56108. ASCs were then cultured until they reached at
least 25 population doublings and harvested at different times of
in vitro expansion, counted and liquid-nitrogen frozen. A total of 6
donors and 36 passages were analyzed (see Table 1 for details). All
molecular analyses were performed on thawed ASCs. When the
amount of recovered cells was low, only selected analyses were
performed.
ASCs Phenotypical Analysis
The phenotype was carried out by flow cytometric analysis for
the CD markers CD14, CD34, CD45, CD73, CD90 (BD
Pharmingen, San Jose´, USA) according to a previously described
method [52]. Briefly, at the first passage, 16105 ASCs were
suspended in flow cytometry buffer (FCB) and then stained with a
saturating amount of conjugated antibodies or their respective
controls. The cells were analyzed using an EPICS XL flow
cytometer (Beckman-Coulter, USA).
Replication Rate
Population doubling (PD) was calculated at each culture
passage, based on recovered vs. seeded cells from the cell count
by using the equation NH/NI= 2PD, where NH=number of
harvested cells and NI=number of seeded cells [53]. The PD
calculated at each passage was then added to the previous PD
level, to yield the cumulative population doubling (CPD) level. For
the first cell passage, the PDs were calculated in relationship to the
CFU-F number in the SVF (P0), according to the following
formula: NH/(NSVF*CF) where NSVF=number of seeded SVF
cells and CF=CFU-F frequency in the SVF population.
Karyotype Analysis
Cytogenetic evaluation was performed by the Laboratoire de
cytoge´ne´tique of the EFS-PM. Thirty metaphases per sample were
evaluated, at selected culture passages, by standard G-banding
karyotype following European guidelines (General Guidelines and
Quality Assurance for Cytogenetics, European Cytogeneticists
Association, http://www.e-c-a.eu).
MicroSatellite Instability (MSI) Analysis
Total DNA from ASC pellets (100,000 cells) was extracted with
the QIAamp DNA Mini Kit (Qiagen GmbH, Germany),
spectrophotometrically quantified and amplified by PCR at five
different microsatellite sequences (CD4, VWA, Fes, Tpox and
Genetic Stability of In Vitro Expanded Human ASC
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P53) as described [54]. PCR products were run on a 10%
polyacrylamide non-denaturing gel together with ladders and
visualized by Sybr green staining. Genetic typing of each sample
was performed by identification of the alleles at each locus by
comparison with ladders made up from a mixture of known alleles.
The allelic patterns were checked for MSI at different in vitro
passages (appearance of allele shifts or additional bands) of each
ASC preparation.
Array-based Gene Expression Analysis
ASC samples from donors displaying a normal karyotype (A, B,
C, E, F) were evaluated at P1 and P5), whereas donor D, showing
karyotype abnormalities, was tested at each available culture
passage (P1, P3, P6 and P7). In addition, donor sample A was also
tested at P14, the most advanced culture passage available. Total
cellular RNA was isolated from the cell pellets (200,000 cells) with
RNA pure isolation reagent (Euroclone, Italy), treated with the
RNase-Free DNase Set (Qiagen, Germany) and cleaned-up in
RNeasy mini columns (Qiagen) following manufacturer’s instruc-
tions, to avoid possibly contaminating DNA. Quantity and quality
of the total RNA for each preparation was determined using a
Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilming-
ton, DE, USA). Total RNA from each sample (0.8 mg) was reverse
transcribed by the RT2 First strand kit (Qiagen). Expression of a
focused panel of 84 genes involved in human DNA Damage
Signaling Pathways together with genomic DNA control, reverse-
transcription control, positive and negative control and five
housekeeping genes (Beta-2-microglobulin, Hypoxanthine phos-
phoribosyltransferase 1, Ribosomal protein L13a, Glyceraldehyde-
3-phosphate dehydrogenase, beta-actin) was evaluated by the RT2
Profiler PCR Array PAHS-029 (Qiagen). Amplification was
performed with the RT2 SYBR Green ROX Fast Mastermix
(Qiagen) in a Rotor-gene 6000 real-time analyzer (Corbett,
Concorde, NSW, Australia). The threshold cycle (Ct) values for
all the genes were calculated and considered as a negative call
when $33. Relative gene expressions were calculated by using the
DDCt method relative to the housekeeping genes showing Ct value
consistency. Results were analyzed by a Web-based PCR Array
Data Analysis Software available at http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php. by comparing samples
at different culture passages and by comparing samples with
normal karyotype to those displaying aneuploidies.
Flow-FISH Determination of Telomere Length
The cells were treated as already described [55]. Briefly,
150,000 ASCs were washed and resuspended in hybridization
buffer (70% deionized formamide, 20 mM Tris buffer pH 7.0,
1%BSA) containing 2.0 mM FITC labeled (CCCTAA)3 peptide
nucleic acid (PNA) probe (Biosynthesis INC, USA), specific for the
telomeric sequence. ASC samples incubated in hybridization
mixture without probe were used as negative controls. Samples
and controls were heat-denatured for 7 min at 80uC and left to
hybridize 2 hours at room temperature in the dark. The cells were
then washed and analyzed by flow cytometry (FACSCanto II
equipped with a 488 nm laser; FITC emission collected through
525/40BP; 5000 events acquired). Telomere fluorescence was
evaluated and expressed as the difference between the geometric
mean fluorescence intensity (MFI) of cells hybridized with
telomere PNA-probe and the corresponding unstained control
sample.
A direct proportionality between mean telomere length and
fluorescence intensity was previously demonstrated in human
lymphocytes by parallel determination of mean telomere length by
Southern blotting (Pearson’s correlation: r = 0.737; p = 0.0001,
unpublished results by Neri S. et al.).
PCR-Elisa Determination of Telomerase Activity
Quantitative determination of telomerase activity was per-
formed using the TeloTAGGG telomerase PCR Elisa Kit
(ROCHE, Germany), a photometric enzyme immunoassay,
following the manufacturer’s instructions. Briefly, extracts were
prepared from 26105 ASCs from each sample and divided into
two aliquots: one was used as the negative control after heat
inactivation of telomerase at 80uC for 30 min, the other was used
to evaluate the telomerase-mediated addition of telomeric
sequences. The products were amplified by PCR and, to exclude
false negative results, a 216 bp length internal standard was
simultaneously amplified. The amounts of hexamers added by the
telomerase contained in each lysate were then evaluated by the
Elisa technique using TTAGGG specific probes. Relative telome-
rase activity (RTA) was calculated for each sample in comparison
with an internal control showing low telomerase activity (low
control = 1026 pmoles of template DNA corresponding to a
product with eight telomeric repeats), after subtraction of the
negative corresponding sample with heat inactivated telomerase
[absorbance reading (As): 450 nm; reference wavelength:
690 nm]. The following formula was used: %RTA= [(As
sample2As heat-treated sample)/As internal standard]/[(As
control template2As lysis buffer)/As internal standard]6100.
The BCR-ABL positive tumor cell line K562 with activated
telomerase [56] was used to compare ASC telomerase activity with
a positive control.
Table 1. Characteristics of ASC analyzed at different culture passages.
Passages [days of culture]
Samples 0 1 2 3 4 5 6 7 9 14
A 7.9 [8] 12.8 [14] 17.2 [21] 21.2 [28] 26.0 [35] 30.2 [42] 34.9 [49] n.d. 45.7 [70] 60.1 [120]
B n.d. 11.2 [14] 14.8 [21] 19.2 [28] 23.5 [35] 27.3 [42] 31.0 [49] n.d. n.d. n.d.
C 7.8 [8] 13.0 [15] 17.7 [23] n.d. 25.4 [36] 29.8 [43] 33.3 [50] n.d. n.d. n.d.
D n.d. 10.6 [14] n.d. 16.2 [28] n.d. n.d. 22.2 [62] 24.8 [96] n.d. n.d.
E 8.1 [8] 12.9 [14] n.d. 21.1 [28] 24.8 [35] 28.6 [42] 31.9 [49] n.d. n.d. n.d.
F 6.4 [8] 10.7 [14] 15.3 [20] n.d. n.d. 28.7 [40] 32.7 [47] n.d. n.d. n.d.
Mean6SD 7.660.8 11.961.1 16.261.4 19.462.3 24.961.1 28.961.2 31.064.5
Cumulative Population Doublings and [days of culture] of all the samples at the different culture passages analyzed are reported.
doi:10.1371/journal.pone.0077895.t001
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Soft Agar Growth
For in vitro testing of anchorage-independent colony develop-
ment, the ASCs of four cases and six passages, namely A (P14), B
(P6), D (P3, P7) F (P0, P2), were cultured in soft agar. The cells
(30,000 per sample) were resuspended in 0.3% Agarose (Sigma,
USA), final concentration, in D-MEM and 10% FCS and
stratified on a bottom layer of 0.5% pre-solidified Agarose in
six-well plates. Plating was performed in duplicate and 1 ml of D-
MEM complete medium was carefully added on the top of each
well to ensure nutritive supplies and to prevent drying. The
medium was changed every two days. Plates were incubated at
37uC and 5% CO2 and evaluated for the presence of colonies at
days 20 and 30. The Saos-2 osteosarcoma cell line, simultaneously
cultured in a separate plate, was used as positive control. A well
containing only the two layers of Agarose and medium was
included in each plate and used as negative control.
Statistical Analysis
Results are expressed as mean6SD (standard deviation) or
6SEM (standard error mean, for phenotype analysis), median and
interquartile ranges, as appropriate. Comparisons among passages
were performed by the Friedman Anova test and between passages
by the Wilcoxon matched pairs test.
Statistical analysis was performed using the Statistica 6 package
for Windows (StatSoft, USA).
Non-supervised hierarchical cluster analysis was used to
compare ASC samples for their expression of DNA damage
signaling genes by a SABiosciences Software (Qiagen) available at
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php.
Results
ASC Growth in Culture
Cells were grown as monolayers for several periods, and then
the cultures were harvested to allow data analysis. All cultures
showed fibroblastic-like cells growing attached to the plastic. As
expected, the cells progressively adopted an enlarged phenotype
when they approached senescence. Culture passages analyzed for
the six donors together with the corresponding CPD and days of
culture are represented in Table 1.
The average number of CPD at the end of P1 (scheduled time
for injection, corresponding to 14 days of culture) was 11.961.14
and 31.064.53 at P6 (corresponding to 51.065.48 days). Sample
A was analyzed until P14 corresponding to 60.1 CPD and 120
days of culture.
Growth curves (Fig. 1) show a low variability in the proliferative
capacity among donors in terms of CPD accomplished in the same
time interval, except for donor D, showing a consistent decrease of
population doublings starting from passage 3, about 15% lower
than the minimum value observed in the passage among samples
and reaching almost 30% decrease at passage 6.
The relationship between CPD and days of culture of all the
analyzed samples is described by a quadratic equation
(CPD=3.3639+0.6663*days 20.0024*days2).
The proliferation rate (CPD number with respect to days of
culture) in the six donor samples progressively decreased with
time, as expected: from 0.94760.096 at P0 to 0.83760.073 at
release time (P1) to 0.69260.028 at P5 (p = 0.043 by Wilcoxon’s
matched pairs test, P1 vs. P5).
Immunophenotype Analysis
ASCs had a classical phenotype at the end of the first passage.
They did not express CD14 or CD45 (1.960.7% and 0.2260.1%,
respectively), they had a very low expression of CD34 (0.660.2%)
and they all expressed CD73 and CD90 (99.760.2% and
99.860.2%, respectively).
Cytogenetic Stability
None of the analyzed samples showed karyotype alterations
until the second culture passage. Three out of six donor samples
(C, E, F) showed no karyotype alterations throughout the culture
period, whereas two donor samples (A and B) showed a sex
chromosome loss at advanced culture as the sole anomaly (Fig. 2).
Specifically, sample A lost the X chromosome at P14 in 97% of
metaphase cells, whereas sample B showed a Y chromosome loss
at P6 in 17% of metaphase cells. Only one donor (sample D)
presented autosomal aneuploidies, which were already present at
P3. In particular, chromosome 10 and 18 trisomies in 7% and
10% of metaphase cells were respectively detected at P3, whereas
chromosome 18 and 20 trisomies in 4% of metaphase cells were
detected at P7, together with a Y chromosome loss in 63% of
metaphase cells (Fig. 2).
Microsatellite Instability Analysis
Allele typing for the six donors at five repeated sequences is
indicated in Fig. 3, as resulting from the analysis performed at
different culture passages. No cases of microsatellite instability
were observed and allele patterns were maintained throughout the
culture period for all the analyzed donors, thus showing that, in
this cellular culture model, repeated replications in vitro did not
alter genetic stability at simple sequence repeats.
DNA Damage Signaling Pathway Expression Profile
To further explore cell response to repeated replications in vitro,
we investigated the gene expression patterns of DNA damage
signaling pathways by RT-PCR arrays. All analyzed ASC samples
were evaluated by non-supervised hierarchical cluster analysis,
grouping samples according to how closely related their gene
expression profiles were (Fig. 4).
Interestingly, two main clusters were highlighted, one contain-
ing all samples, except sample D, at all analyzed passages, and the
other containing sample D at the four different passages analyzed
(P1, P3, P6 and P7). In particular, the finding of all sample D
passages in a separate cluster, suggests a general different behavior
for this donor sample that seems to be independent of culture
passages. Coincidently, sample D was the only one showing a
consistent slowdown of the population doublings starting from
Figure 1. Growth curves. The continuous line represents the
regression fit of all the samples. The upper dashed line represents the
regression fit of samples excluded sample D. The lower dashed line
indicates the regression fit of sample D alone.
doi:10.1371/journal.pone.0077895.g001
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initial culture passages (Fig. 1) and the only one displaying
autosomal chromosome alterations during culture (Fig. 2).
Semi-quantitative gene expression analysis was focused on
highly responsive genes: a 2-fold change threshold for up- and
down-regulation was applied (p#0.05). To assess the effect of
in vitro culture time on DNA damage-related gene expression, we
compared samples at P1 with those at P5 and the only available
sample at P14. We observed very few genes whose expression was
significantly modified between P1 and P5 (Table 2), notably, all
Figure 2. Karyotype. Data are summarized in the table (above) and refer to 30 analyzed mitoses for each sample. Three abnormal karyotypes are
shown (below). N= normal karyotype; n.d. = not determined.
doi:10.1371/journal.pone.0077895.g002
Figure 3. Microsatellite instability (MSI) analysis. On the left: MSI analysis of sample A is shown as an example. Allele patterns for each of the
five analyzed microsatellite sequences (CD4, VWA, Fes, Tpox and P53) were identified by acrylamide gel separation and compared among culture
passages (P1, 2, 4, 6, 9 and 14). Each allele pattern appears to be stable throughout the culture period. On the right: Table summarizing MSI analysis
of the 6 ASC samples. Allele nomenclature refers to the number of repeats [47]. For each ASC sample, allele patterns for the five analyzed
microsatellite loci (CD4, VWA, Fes, Tpox and P53) were maintained at all the different analyzed culture passages.
doi:10.1371/journal.pone.0077895.g003
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significantly modified genes showed a reduced expression, thus
indicating a general down-regulation due to culture time.
This behavior was even more evident at P14, even if the
availability of only one sample at this passage did not allow
statistical analysis to be performed (Table 2).
Whereas sample D at the beginning of the culture was
indistinguishable from the other ones, culture time induced an
up-regulation of some genes not observed in samples with normal
karyotype.
In particular, sample D at P7 showed an up-regulation of BTG2
(B cell Translocation Gene family member 2, NM_006763; 4.50
folds), GADD45G (Growth arrest and DNA-damage-inducible,
gamma, NM_006705; 4.18 folds), IP6K3 (Inositol hexakipho-
sphate kinase 3, NM_054111; 15.45 folds), MAP2K6 (Mitogen-
activated protein kinase kinase 6, NM_002758; 9.61 folds) genes
compared to samples with normal karyotype at P5.
In agreement with the absence of microsatellite instability,
MMR gene expression (MLH1, MSH2, PMS1, PMS2, MLH3
and PCNA), as evaluated by array analysis, showed no significant
modification until very advanced culture passages.
Telomere Length and Telomerase Activity
Telomere length expressed as mean fluorescence intensity
showed an inter-individual variability, independently of donor
ages and culture passages. In each subject, ASC showed a low
degree of random fluctuation in the telomere dynamics (sample A
is reported by way of example, Fig. 5).
A general negative trend during in vitro culture was noticed even
if no significant telomere length differences were observed within
passages from 0 to 6, as determined by the Friedman ANOVA
test. Medians and [interquartile ranges] of fluorescence intensity
were: 423.5 [381.0–445.0] at P0; 435.0 [414.0–435.0] at P1; and
390.5 [371.5–419.0] at P6.
Relative telomerase activity (RTA) was permanently undetect-
able in the majority of samples (78.3%). Few samples (17.4%)
displayed a marginal telomerase activity (ranging from 0.4 to 78%
of the low control provided in the kit), mainly at the beginning of
the culture period, within the second passage. Only one sample
(sample C at passage 0) showed a little bit higher RTA (248% of
the low control), that was no more observed in the following
passages. This RTA was however remarkably lower than the
activity measured in the K562 tumor cell line used as positive
control (%RTA: 5266), therefore these results are considered
essentially as negative.
Soft-agar Growth
A (P14), B (P6), D (P3, P7) F (P0, P2) samples (intentionally
tested at passages displaying karyotype alterations) showed no
anchorage-independent growth in soft agar after 20 and 30 days,
thus indicating no malignant transformation, even when samples
Figure 4. Gene expression analysis. Dendrogram obtained by hierarchical clustering of 6 ASC samples (A–F) at different culture passages (P, from
1 to 14) based on the expression of 84 genes involved in DNA damage signaling pathways. Gene expression levels are shown as a heat map for each
gene.
doi:10.1371/journal.pone.0077895.g004
Table 2. Effect of culture expansion on DNA damage signaling pathway gene expression.
P1 vs P5 P1 vs P14
Symbol Accession Description P value Fold changes P value Fold changes
BRCA1 NM_007294 Breast cancer 1 0.0002 28.82 n.a. 27.36
DMC1 NM_007068 Dosage suppressor of mck1 homolog, meiosis-specific
homologous recombination
0.0008 211.11 n.a. 229.38
EXO1 NM_130398 Exonuclease I n.s. 24.24 n.a. 216.05
FEN1 NM_004111 Flap structure-specific endonuclease I 0.0015 24.93 = = = = = =
GML NM_002066 Glycosylphosphatidylinositol anchored molecule like protein = = = = = = n.a. 24.35
GTSE1 NM_016426 G2 and S-phase expressed I 0.0103 217.09 n.a. 222.61
IP6K3 NM_054111 Inositol hexakiphosphate kinase 3 = = = = = = n.a. 24.07
XRCC2 NM_005431 X-ray repair complementing defective repair in Chinese
hamster cells 2
= = = = = = n.a. 27.02
Results from RT-PCR array analysis are shown as fold changes between P1 (n = 6) and P5 (n = 4) or P14 (n = 1).
n.a. = not applicable; n.s. = not significant.
doi:10.1371/journal.pone.0077895.t002
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from the more advanced passages were cultured (not shown).
Conversely, Saos-2 positive control cells grown in the same
conditions were able to form colonies (not shown).
Discussion
Regenerative medicine offers great promise for osteo-cartilagi-
neous medical applications and safety is emerging as critical issue,
particularly when in vitro cell processing is performed before
therapeutic approaches. In Europe, MSCs are considered
advanced therapy medicinal products referring to the European
GMP rules. Production processes need to ensure not only
microbiological safety, but also genetic stability in order to avoid
transformation risks. Only few papers have reported transforma-
tion in culture of human mesenchymal stem cells [36] and some of
these reports have been retracted [37–40] because transformation
was found to be due to cross-contaminating cancer cells. However,
it has been shown that in vitro culture induces chromosomal
aberrations, which are a hallmark of human cancer. Despite the
conflicting results about the neoplastic transformation of human
MSC, it should be mentioned that no cases of tumour formation
have been documented in human patients after MSC treatment
for a variety of indications (over 1000 patients treated until 2012)
[1].
Anyway, it appears crucial to perform a detailed analysis of the
genome prior to any cell-based treatment. No international
indications about genetic stability assessments have been provided
and karyotyping is the most frequently used analysis, even if its
sensitivity (in the order of Mb) does not allow small molecular
change detection; therefore possible genetic abnormalities might
be underestimated.
The relevance of the clear tendency towards increased
aneuploidy with culture passages is still being debated [33,35]. It
seems that each type of stem cell is prone to acquire specific
chromosomal aberrations, and that these aberrations are fre-
quently the same that occur in tumors of the respective tissue [31].
Recurrent aberrations in MSCs may simply imply the acquisition
of a growth advantage or they may indicate the beginning of a
transformation process in culture [35].
The scientific community would benefit from large scale studies
evaluating common genetic changes occurring during in vitro
culture and their significance to avoid excessively high restrictions
to MSC-based promising therapies [57]. However, monitoring of
genomic stability should be performed regularly to ensure safe
administration and this is particularly crucial for non-life
threatening pathologies such as osteoarthritis. The European
AdipoA project is a multi-dose phase I clinical trial for therapeutic
applications of ASCs in human knee OA and a phase II controlled
study. At present, the clinical phase is in progress and the follow up
is ongoing. Pre-clinical studies on clinical grade ASC performed by
other groups involved in this project suggested a paracrine role of
ASC cells in the diseased articulation. Indeed, ASCs were
demonstrated to reduce hypertrophy and maintain chondrocyte
phenotype in co-culture with primary OA chondrocytes, partly
through HGF secretion [58] and COX-2/PGE2 pathway
involvement [59]. However, injected ASC seem to persist in vivo
in the host as demonstrated in animal models. SCID mice
receiving intrarticular injection of human ASCs showed 15% of
the injected cells detectable in the joint in the first month and
1.5% engrafted over the long term [60]. In an experimental rabbit
model of OA, the short term local bio-distribution of autologous
injected ASCs revealed a localization of the cells in the synovium
but not in the cartilage, supporting their prevalent trophic effect in
inhibiting OA progression [61].
In this study, the impact of in vitro culturing of adipose-derived
stromal cells on genetic stability has been addressed, which would
have an impact on the quality control in cell therapies. In our case
series of ASC samples, we observed a proliferation rate slowdown
with culture passages, as expected, very similar in all samples
except one, showing early deceleration of growth, thus indicating a
peculiarity of this donor sample.
No karyotype alterations were observed in culture passages
preceding in vivo injection (end of P1). Conversely, sex chromo-
some aneuploidies were detected in three out of six samples, only
at advanced PD. The phenomenon of sex chromosome loss has
already been described with aging [62–66], therefore it might be
interpreted as a non-phenotypic event, related both to donor age
and culture time. In accordance, the phenomenon was detected
only at the most available advanced PD for all the three samples
even if no statistical significance was found neither with donor age
nor with culture time, probably due to the reduced number of
samples. Once again, no autosomal aneuploidies were detected
Figure 5. Telomere length dynamics in culture. Geometric mean of fluorescence intensity is reported at different culture passages relative to
sample A, as representative example.
doi:10.1371/journal.pone.0077895.g005
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except in sample D at P3 and P7. This donor did not show clinical
peculiarities and neither his age nor gender were correlated with
the appearance of autosomal abnormalities, therefore we can only
speculate about these findings supposing a particular susceptibility
of the cells of this donor in culture. In general, as the incidence of
aberrations increases with culture passages, and no clear evidence
of the role of such alterations was provided, minimizing the culture
time is a way to decrease the chance for in vitro genetic alterations
and to guarantee safety.
Concerning the stability of short repeated sequences in the
genome, no cases of MSI in the five analyzed loci were detected,
suggesting that genomic stability at short repeated sequences is
maintained overtime. In agreement with this, no significant
modifications of MMR gene expression, whose activity is required
for the stability of short repeated sequences, was noticed by array-
analysis. These results differ from those obtained in other cellular
models of in vitro expansion, where a positive correlation between
MSI phenotype and culture extension was observed [48–49,67–
69]. Moreover, ASCs do not seem to develop the microsatellite
instability displayed by human hematopoietic progenitor cells as a
function of age [50].
Array-based gene expression analysis for genes involved in DNA
damage signaling pathways showed a general down-regulation of a
few genes with culture time, namely BRCA1, DMC1, EXO1,
FEN1, and GTSE1, which more likely mirrors in vitro aging than
initial processes towards transformation. Indeed, global changes in
mRNA expression profiles of human BM-MSCs cultured to
senescence were described with culture time and, in particular, a
progressive down-regulation of genes involved in DNA repair and
metabolism were observed [70].
BRCA1 is a tumor suppressor gene with a fundamental role in
genomic stability maintenance, involved in DNA damage repair,
chromatin remodeling and checkpoint activation and BRCA1-
defective cells are significantly impaired in the main DNA repair
mechanisms [71–72]. The down-regulation of this gene might
therefore indicate a reduced ability of ASCs at advanced culture
passages to respond and correct occurring DNA alterations, with
an augmented chance of accumulating DNA damage. DMC1 is a
meiosis-specific recombinase, a member of the RecA/Rad51
recombinase superfamily that functions in homologous recombi-
nation with the ubiquitously expressed homolog Rad51 gene [73].
The down-regulation of the DMC1 gene probably has no
functional effect, as this gene’s activity is only required during
meiosis. EXO1 endonuclease has been implicated in a multitude
of eukaryotic DNA pathways including repair, recombination,
replication and telomere integrity maintenance [74]. It is involved
in mutation avoidance pathways both MMR-dependent and
independent. As for BRCA1, its down-regulation might increase
the mutation rate. FEN1 is a multifunctional nuclease, a member
of the Rad2 family, participating in distinct DNA metabolic
pathways including DNA replication and repair, telomere
maintenance and apoptotic DNA fragmentation, whose inactiva-
tion results in genomic instability [75]. GTSE1 protein is almost
undetectable in the G1 phase, whereas it increases during S and
peaks in the G2 phase of the cell cycle. In response to DNA
damage it accumulates in the nucleus and binds p53 repressing its
ability to induce apoptosis [76]. The observed reduced expression
of its mRNA might reflect the reduced percentage of dividing cells
at advanced culture times.
Sample D, showing autosomal aneuploidies, also displayed a
different gene expression pattern at advanced PD with few genes,
all upregulated: BTG2, involved in cell cycle regulation with anti-
proliferative activity [77]; GADD45G, whose transcript levels are
increased following stressful growth arrest conditions, participating
in cell cycle arrest, DNA repair, cell survival and apoptosis in
response to environmental and physiological stress, as well as
having a role in development and carcinogenesis [78]; IP6K3
phosphokinase and MAP2K6, dual specificity protein kinases that
activate p38 MAP kinase, involved in apoptosis, stress response
and transcriptional regulation [79]. Conclusions about these data
can only be speculative, since they came from only one sample, but
they might be correlated with the different behavior of this donor
sample compared to that of the others in terms of replication rate
slowdown and chromosomal stability, thus suggesting a patient-
dependent profile.
We also observed that ASCs lack detectable telomerase activity
in agreement with other reports [80–81], thus suggesting that these
cells are not prone to transformation in vitro. Given this
observation, concomitant telomere erosion was expected; howev-
er, only a slight trend of telomere attrition over culture time was
observed, which was less evident than that revealed, by
densitometric analysis, in few ASC samples from various
anatomical sites [82]. Although ASCs were observed for several
passages, cumulative evaluations were performed until P6, when
the growth curves were still nearly linear and before the pre-
senescent/senescent phase, which is expected between P10 and
P20, as reported by others [21]. However, it cannot be excluded
that, as described in synchronized cultures of bone marrow
mesenchymal stem cells [83], also the present ASC populations
display telomerase activity during the S phase, but this activity is
hidden in the present asynchronous culture system.
Overall, the present results argue for the absence of genetic
damage accumulation at the first culture passages and their
occasional appearance at advanced passages only in specific cases,
thus pointing to the importance of reducing culture times as much
as possible. It is however noteworthy that even samples showing
chromosomal alterations did not display anchorage-independent
growth, in favor of the hypothesis that these changes do not foster
a selective growth advantage in vitro to abnormal cells.
Conclusions
A panel of analyses were performed including both cytogenetic
and molecular DNA damage evaluation showing that, after
repeated duplications in vitro in defined culture conditions, human
adipose stromal cells do not show alterations in either chromosome
or short repeated sequences, do not show telomere attrition, do not
express significant amounts of active telomerase and do not
acquire anchorage-independent growth ability, and all data
support their safety for therapeutic use.
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